We have recently reported that bcl-2 overexpression and hypoxia synergistically interact to modulate vascular endothelial growth factor (VEGF) and in vivo angiogenesis in tumour cells through VEGF mRNA stabilization and hypoxia-inducible factor 1-mediated transcriptional activity. Bcl-2 antisense treatment has shown promising clinical results in patients with malignant melanoma. In the present study, we demonstrated that the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 inhibits bcl-2 expression and angiogenesis in two bcl-2 overexpressing clones derived from the M14 human melanoma cell line. The antiangiogenic effect was determined in in vitro and in vivo angiogenesis assays. In particular, a reduction of hypoxia-induced VEGF secretion was observed after 4625 treatment, and the conditioned medium (CM) of bcl-2 overexpressing clones treated with 4625 and exposed to hypoxic conditions resulted in decreased endothelial cell proliferation when compared to CM of untreated control cells. In addition, we found that CM of 4625 antisensetreated bcl-2 transfectants inhibited in vivo vessel formation in matrigel plugs implanted subcutaneously in C57/ B16 mice. Our findings confirm that bcl-2 plays a crucial role in melanoma angiogenesis and demonstrate for the first time that downregulation of bcl-2 by antisense treatment has potential to inhibit angiogenesis independent of its effect on cell survival. The use of 4625 in cancer therapy is suggested as an approach to facilitate simultaneously tumour cell apoptosis and inhibit tumour angiogenesis.
Introduction
Angiogenesis, which is the formation of new blood vessels from pre-existing capillaries, plays an important role in tumour development, progression and metastasis (Folkman, 1986) . It involves well coordinated steps including the production and release of angiogenic factors, proteolytic degradation of extracellular matrix components to allow formation of capillary sprout, proliferation and directional migration of microvascular cells, and the final composition of new vessels (Ruoslaty, 2002) . To develop in size and metastatic potential, tumours must undergo an 'angiogenic switch' through perturbing the local balance of proangiogenic and antiangiogenic factors (Hanahan and Folkman, 1996; Ruoslaty, 2002) . Most frequently, tumours achieve this goal by overexpressing proangiogenic factors.
The finding that the growth and spread of tumours are dependent on angiogenesis has raised interest in the multiple molecular mechanisms underlying tumour development and malignant progression, and has stimulated the devise of new antiangiogenic strategies (Cristofanilli et al., 2002) . A group of growth factors, including fibroblast growth factor, platelet-derived growth factor and vascular endothelial growth factor (VEGF) and their corresponding receptor tyrosine kinases, have become the focus of investigations to inhibit the proliferation of endothelial cells as the main components of blood vessels (Millauer et al., 1994; Bergers et al., 1999; Jain, 2002) . Targets for inhibition of angiogenesis also include a family of matrix metalloproteinases and cell adhesion molecules (Brooks et al., 1994; Moses, 1997) . In addition, protein kinases have emerged as important targets for drug discovery in angiogenesis research (Fong et al., 1999; Klagsbrun and Moses, 1999; McCarthy, 2001) . Besides growth factor receptor tyrosine kinases, numerous other protein kinases implicated in malignancies have been identified, including nonreceptor kinases such as bcr-abl and src kinases (Mukhopadhyay et al., 1995; Druker et al., 2001; Rak et al., 2002) . In addition, the cell cycle regulators cyclin-dependent kinases, p21 and apoptosis modulators such as bcl-2, p53 or the inhibitor of apoptosis proteins survivin have also raised renewed interest as potential targets for cancer therapy (Folkman, 2002; Nam and Parang, 2003) .
The two mechanisms most widely employed by antiangiogenic agents are inhibition of proangiogenic factors (e.g., anti-VEGF monoclonal antibodies) and endogenous inhibition of angiogenesis (e.g., endostatin and angiostatin) Presta et al., 1997; Moser et al., 1999; Folkman, 2000) . Antiangiogenic agents are effective against a wide variety of tumours. Moreover, they can overcome some of the limitations observed with conventional cytotoxic agents, which nonspecifically induce damage and apoptosis in cells. After realizing the potential advantages of antiangiogenic therapy, the field of angiogenesis research has expanded exponentially. Today there is a vast amount of literature that serves as proof-of-concept for the use of angiogenic inhibitors as highly effective agents to block tumour-induced angiogenesis and subvert tumour growth and dissemination . One of the unique attractions of targeting tumour angiogenesis is that vascular endothelial cells are a genetically stable population in which acquisition of therapeutic resistance might be less efficient than in the genetically unstable tumour cell population .
We previously demonstrated that bcl-2 overexpression increases the metastatic potential of a human breast tumour cell line (Del Bufalo et al., 1997) . In addition, we have recently reported that bcl-2 overexpression and hypoxia synergistically interact to modulate VEGF and in vivo angiogenesis in human breast carcinoma and melanoma cell lines (Biroccio et al., 2000; Iervolino et al., 2002) . Moreover, bcl-2 overexpression in melanoma cells increases angiogenesis through VEGF mRNA stabilization and hypoxia-inducible factor 1-mediated transcriptional activity (Iervolino et al., 2002) . A better understanding of the role that bcl-2 plays in the angiogenic process may assist in the development of more effective cancer therapies.
In the present study, we investigated the ability of the bcl-2/bcl-xL bispecific oligonucleotide 4625 (Zangemeister-Wittke et al., 2000) to downregulate bcl-2 and bcl-xL expression, and inhibit angiogenesis in human melanoma cells. Previous results demonstrated that bcl-2 modulates angiogenesis synergistically with hypoxia (Biroccio et al., 2000; Fernandez et al., 2001; Iervolino et al., 2002) , which is the most potent activator of VEGF, and that solid tumours can grow under low oxygen pressure. Therefore, to mimic the in vivo situation, we investigated the effect of oligonucleotide 4625 under hypoxic conditions.
Results

Effect of antisense oligonucleotide 4625 on apoptosis induction
We previously demonstrated that bcl-2 overexpression in melanoma and breast carcinoma cells increases hypoxia-induced VEGF expression and angiogenesis (Biroccio et al., 2000; Iervolino et al., 2002) . To investigate whether treatment with 4625 has potential to modulate VEGF secretion and angiogenesis in melanoma cells, two bcl-2 overexpressing clones (MB5, MB6) were used. These clones were derived from the M14 melanoma cell line. They show an increased angiogenic ability mainly related to bcl-2 overexpression which cooperates with hypoxia in increasing VEGF secretion (Iervolino et al., 2002) .
The ability of 4625 to induce apoptosis in several tumour histotypes has been described (ZangemeisterWittke et al., 2000; Gautschi et al., 2001; Olie et al., 2002a, b) . To exclude the possibility that the decrease in cell survival induced by 4625 affects the expression of VEGF protein, conditions were chosen under which 4625 did not activate the apoptotic programme in the cells. For this purpose, and on the basis of our previously published results (Zangemeister-Wittke et al., 2000; Olie et al., 2002a, b; Gautschi et al., 2001) , the bcl-2 transfectants were treated with 300 or 600 nm oligonucleotide for 6 or 20 h, and exposed to hypoxia for 24 h. A pool of detached and adherent cells was analysed by flow cytometry for DNA content and by TUNEL staining. As shown in Figure 1 , we found that transfection with 300 nm 4625 for 6 h followed by 24 h of hypoxia did not induce apoptosis, while transfection with the same dose for 20 h followed by hypoxia induced apoptosis in about 18% of the cells. After treatment with 4625 at 600 nm for 6 and 20 h followed by hypoxia, sub-G1 peaks, indicative of apoptotic cell death, revealed 20 and 30% dead cells, respectively. No significant difference was observed between untreated and control sequence 4626-treated cells after 6 and 20 h of treatment for both oligonucleotide concentrations. From Figure 1 it is also evident that hypoxia did not induce apoptosis under these experimental conditions. Less than 5% of apoptotic cells were observed in bcl-2 transfectants exposed to hypoxia demonstrating that apoptosis induction was only due to the effect of oligonucleotide 4625. All these results were confirmed by in situ TUNEL assays. Figure 2 shows the results of an in situ TUNEL assay with a representative bcl-2 overexpressing clone treated for 6 h with 300 and 600 nm 4625 or 4626, and then exposed to hypoxia for 24 h. The data confirmed the absence of apoptotic cells after treatment with 4626 control sequence and after exposure for 6 h to 300 nm 4625. On the contrary, treatment with 600 nm 4625 for 6 h induced apoptosis in about 25% of the cells. Therefore, a 6 h transfection with 300 nm 4625 or 4626 followed by 24 h hypoxia was used in all subsequent experiments.
Effect of oligonucleotide 4625 on bcl-2 and bcl-xL protein expression
To evaluate whether 4625 was able to downregulate the expression of bcl-2 and/or bcl-xL proteins, MB5 and MB6 bcl-2 overexpressing clones were treated with 300 nm 4625 or the control sequence 4626 for 6 h prior to hypoxia exposure for 24 h. Western blot analysis of bcl-2 and bcl-xL protein expression was performed at the end of hypoxia exposure.
As shown in Figure 3 , a 6 h treatment with 4625 followed by 24 h hypoxia decreased bcl-2 protein expression by about 60%, and also bcl-xL slightly (between 15 and 25%). No effect on bcl-2 protein expression was observed after treatment with the control sequence 4626. Moreover, exposure of the bcl-2 overexpressing cells to hypoxia for 24 h did not induce changes in bcl-2 or bcl-xL protein expression, and (4626), and then exposed to hypoxia for 24 h. The analysis was performed at the end of oligonucleotide/hypoxia treatment. The DNA content after 24 h exposure to normoxia is also reported. A representative experiment out of three is shown Figure 2 Detection of apoptosis by in situ TUNEL staining in MB5 bcl-2 overexpressing clone untreated or treated for 6 h with 300 or 600 nm antisense oligonucleotide 4625 (4625) or control sequence 4626 (4626), and then exposed to hypoxia for 24 h. The analysis was performed at the end of oligonucleotide/hypoxia treatment. A representative experiment out of three is shown
Bcl-2 antisense induces antiangiogenic activity D Del Bufalo et al similar levels of bcl-2 and bcl-xL expression were observed when cells were grown under normoxic or hypoxic conditions.
Effect of antisense oligonucleotide 4625 on hypoxia-induced VEGF secretion
To investigate whether bcl-2 protein downregulation was able to inhibit VEGF secretion, MB5 and MB6 bcl-2 overexpressing clones were treated for 6 h with 300 nm 4625 or 4626 and then exposed to hypoxia for 24 h. At the end of hypoxia exposure, VEGF levels in conditioned medium (CM) were quantified. As reported previously (Iervolino et al., 2002) , bcl-2 transfectants exposed to hypoxia secrete about threefold more VEGF than under normoxic conditions (Figure 4 ). Treatment with 4625 resulted in about 50-60% reduction of VEGF in the CM of both cell clones, whereas treatment with control sequence 4626 did not alter VEGF levels.
Effect of antisense oligonucleotide 4625 on in vitro and in vivo angiogenesis
The functional activity of the secreted VEGF was examined by measuring HUVEC and HMVEC cell proliferation, and by use of an in vivo matrigel assay in the presence of CM from bcl-2 transfectants untreated and treated with 4625 or 4626 prior to hypoxia exposure for 24 h. Figure 5 shows that HUVEC proliferation after exposure to CM derived from two untreated bcl-2 overexpressing clones was similar to that of endothelial cells grown in the presence of serum (positive control). In contrast, CM from two bcl-2 transfectants treated with 4625 reduced cell proliferation by about 60% when compared to CM from untreated bcl-2 transfectants. The CM from bcl-2 transfectants treated with the control sequence 4626 did not affect endothelial cell proliferation. Similar results were obtained when HMVEC cells were used (data not shown). We next investigated whether the decrease in VEGF secretion in cells induced by 4625 resulted in decreased in vivo angiogenesis. For this purpose, matrigel plugs containing CM obtained from cells after treatment with 4625 or 4626 followed by 24 h of hypoxia were injected subcutaneously in mice, and the degree of vascularization into matrigel plugs was examined after 5 days ( Figure 6 ). The CM of the bcl-2 transfectants treated with 4625 showed a reduced angiogenic response as compared with the response seen by CM of untreated or 4626-treated bcl-2 transfectants (Figure 6a) . Evaluation of the angiogenic response by measuring the hemoglobin content in matrigel plugs demonstrated that those Figure 3 Bcl-2 and bcl-xL protein expression after treatment of MB5 (a) and MB6 (b) bcl-2 overexpressing clones for 6 h with 300 nm antisense oligonucleotide 4625 (4625) or control sequence 4626 (4626). At the end of oligonucleotide treatment, cells were exposed to hypoxia for 24 h. Western blot analysis was performed at the end of oligonucleotide/hypoxia treatment. Bcl-2 and bcl-xL protein expression of cells grown under normoxic conditions is also reported, b-Actin was used as a control for equal protein loading. A representative experiment out of three is shown Figure 4 Expression of VEGF protein in conditioned medium (CM) of MB5 (black column) and MB6 (grey column) bcl-2 overexpressing clones untreated or treated for 6 h with 300 nm antisense oligonucleotide 4625 (4625) or control sequence 4626 (4626). At the end of oligonucleotide treatment, cells were exposed to hypoxia for 24 h and VEGF protein secretion quantified in the CM. VEGF protein secretion was also analysed 24 h after exposure to normoxia. The mean values (7s.d.) of four independent experiments are reported Figure 5 HUVEC endothelial cell proliferation induced by conditioned media (CM) obtained from MB5 (dark grey column) and MB6 (grey column) bcl-2 overexpressing clones. Exponentially growing endothelial cells were seeded and incubated for 24 h in complete medium. Thereafter, cells were starved for 24 h in serumfree medium (SFM), and then incubated in SFM (white column, negative control), in complete medium (white column, positive control), or the CM obtained from the different lines untreated or treated for 6 h with 300 nm oligonucleotide 4625 (4625) or the control sequence 4626 (4626), and exposed to hypoxia for 24 h. Cell proliferation was measured after 48 h. Bars represent the mean7s.d. of one representative experiment out of three Bcl-2 antisense induces antiangiogenic activity D Del Bufalo et al containing CM from untreated-bcl-2 transfectants had a significantly higher (10-12-fold, Po0.001) level of hemoglobin than matrigel plugs containing CM from 4625-treated cells (Figure 6b ).
Discussion
The involvement of bcl-2 in angiogenesis has been demonstrated in various human tumour histotypes (Biroccio et al., 2000; Fernandez et al., 2001; Iervolino et al., 2002) and in endothelial cells (Nor et al., 1999 (Nor et al., , 2001 Schechner et al., 2000) . The expression of VEGF and the angiogenic potential of human breast carcinoma, prostate and melanoma cells exposed to hypoxia are increased after bcl-2 overexpression (Biroccio et al., 2000; Fernandez et al., 2001; Iervolino et al., 2002) , and upregulation of bcl-2 in human endothelial cells enhances the number of capillary-like sprouts and the density of vascular structures (Nor et al., 1999 (Nor et al., , 2001 Schechner et al., 2000) . Since bcl-2 is an inhibitor of apoptosis and confers varying degrees of resistance to chemotherapy (Biroccio et al., 1999; Del Bufalo et al., 2001 ) dependent on the drugs used (Del Bufalo et al., 2002a, b) , a better knowledge of bcl-2 role in angiogenesis may help to design more effective combination therapies.
In this paper, we have assessed the antiangiogenic effect of the bcl-2/bcl-xL bispecific antisense oligonucleotide 4625 on melanoma cells. For this purpose, two bcl-2 overexpressing clones, derived from the M14 human melanoma cell line (Iervolino et al., 2002) , were treated with 4625. We previously demonstrated that bcl-2 overexpression and hypoxia synergistically interact to modulate VEGF expression and in vivo angiogenesis in cancer lines, and that regions of low oxygen tension are a unifying feature of solid tumours. Therefore to mimic the in vivo situation bcl-2 overexpressing clones were exposed to hypoxia after treatment with oligonucleotides. To exclude that the modulation of angiogenesis by 4625 was due to decreased cell survival, 4625 was used under conditions that did not induce apoptosis. This treatment was still able to decrease bcl-2 protein significantly and also bcl-xL expression slightly. Despite, the bispecific activity of 4625, the prevalence of the bcl-2 mRNA, which competes with the mismatching bcl-xL mRNA for oligonucleotide binding, resulted in the diminution of the bcl-xL antisense effect. In addition, we could exclude the possibility that bcl-2 was modulated by hypoxia. In fact, even though hypoxia has been demonstrated to upregulate bcl-2 expression both in human tumour-derived endothelial cells (Kinoshita et al., 2001 ) and in cancer cell lines (Wang et al., 2002) , no alterations in the expression of bcl-2 protein were observed in our model system after 24 h of hypoxia.
We found that 4625 also reduced VEGF levels in the bcl-2 transfectants by 50-60% compared with untreated control cells. This decrease is in agreement with our previous results demonstrating that bcl-2 overexpression in human melanoma cells increases VEGF production through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity (Iervolino et al., 2002) .
The finding that the use of 4625 reduced endothelial cell proliferation and matrigel vascularization confirms the relevance of bcl-2 for melanoma angiogenesis, and suggests a possible role of bcl-xL in this phenomenon. In particular, the CM of bcl-2 transfectants treated with 4625 and grown under hypoxic conditions decreased endothelial cell proliferation when compared to CM of untreated control cells. The in vitro antiangiogenic activity of CM from 4625-treated bcl-2 overexpressing clones was confirmed in an in vivo angiogenic assay. A strong inhibition of vessel formation in matrigel plugs was observed when the CM of bcl-2 transfectants treated with 4625 was used.
Furthermore, our results demonstrate the ability of antisense oligonucleotide 4625 to induce apoptosis in melanoma cells. As shown in previous studies Figure 6 In vivo angiogenesis assessed after injection on C57BL/6 mice with matrigel containing conditioned medium (CM) from MB5 and MB6 bcl-2 transfectants untreated or treated for 6 h with 300 nm oligonucleotide 4625 (4625) or the control 4626 (4626), and exposed to hypoxia for 24 h. After 5 days, mice were killed and neovascularization was assessed. Zangemeister-Wittke et al., 2000; Gautschi et al., 2001; Koty et al., 2002; Olie et al., 2002a, b) , 4625 facilitates tumour cell apoptosis in a time-and dose-dependent manner in vitro, and when administered in vivo as single agent caused inhibition of human breast and colon carcinoma xenografts in mice (Gautschi et al., 2001) . In combination experiments, 4625 sensitized breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide (Simoes-Wust et al., 2002) . Recently, the combination of 4625 with targeted inhibition of epidermal growth factor receptor and protein kinase A type I resulted in strong antiproliferative, proapoptotic and antiangiogenic responses (Tortora et al., 2001 (Tortora et al., , 2003 . Owing to the potent proapoptotic effect of oligonucleotide 4625, we used experimental conditions under which treatment of melanoma cells with 4625, as well as exposure to hypoxia alone, did not induce apoptosis per se, regardless of the basal bcl-2 expression levels in the cells (Iervolino et al., 2002) . Our results demonstrate, for the first time, that the use of 4625 antisense oligonucleotide not only lowers the apoptotic threshold in cells, but also inhibits angiogenesis which is independent of the proapoptotic effect. Together with our previously published work, the present study demonstrates the potential of 4625 as both an inducer of apoptosis and a negative modulator of angiogenesis, and provides a rationale basis for the use of the bcl-2/ bcl-xL bispecific antisense oligonucleotide 4625 in combination therapies to enhance the efficacy of chemotherapy and inhibit tumour angiogenesis. The antiangiogenic activity of 4625 suggests the use of bcl-2 antisense oligonucleotides, including G3139 which is currently undergoing phase III clinical testing in melanoma patients (Jansen et al., 2000; Waters et al., 2000) , for targeted therapy of early primary melanoma tumours and metastasis.
Materials and methods
Cell lines and oligonucleotide treatment
Two bcl-2 overexpressing clones (MB5, MB6) previously derived from M14 human melanoma cells (Iervolino et al., 2002) were maintained in RPMI medium containing 10% fetal calf serum (FCS), 2 mm l-glutamine, antibiotics and neomicine (G418, 800 mg/ml, Invitrogen, Milan, Italy).
Human umbilical endothelial cells (HUVEC) were kindly provided by Dr Carlo Gaetano (Istituto Dermopatico dell'Immacolata, Rome, Italy) and cultured in complete EBM-2 medium (Clonetics Bio Whittaker), containing 2% fetal bovine serum (FBS).
Human microvascular endothelial cells (HMVEC) were kindly provided by Dr Gabriella Fibbi (Department of Pathology and Oncology, University of Florence, Italy) and maintained in MCDB-131 medium (Invitrogen) supplemented with 0.3% FCS.
Oligonucleotides were delivered into cells in the form of complexes with the transfection reagent lipofectin (Invitrogen) as described previously (Zangemeister-Wittke et al., 2000) . The bcl-2/bcl-xL bispecific 2 0 -O-(methoxy)ethyl (2 0 -MOE)-modified gapmer antisense oligonucleotide 4625 is fully complementary to the bcl-2 mRNA and has three mismatching nucleotides to the bcl-xL mRNA (Zangemeister-Wittke et al., 2000) . Oligonucleotide 4626 is a scrambled sequence control to 4625.
Bcl-2 transfectants were seeded and grown for 24 h in complete medium, incubated for 6 or 20 h in the presence of 300 or 600 nm oligonucleotides and then exposed in serum-free medium (SFM) under hypoxic conditions for 24 h as reported previously (Biroccio et al., 2000) . Cells and CM were differentially processed according to the analysis to be performed.
Apoptosis, ELISA and Western blot analysis
To measure the percentage of apoptotic cells, cells floating in the culture supernatants were collected by centrifugation and pooled with adherent cells recovered from the plates. DNA fragmentation was analysed by flow cytofluorimetric analysis of sub-G1 peaks as described (Del Bufalo et al., 1996) . TdT-mediated dUTP-biotin nick-end labeling assay (TUNEL) was performed using the APO-BRDU kit (BioSource International, Camarillo, CA, USA) and cytofluorimetric analysis was performed as described previously (Del Bufalo et al., 2002b ).
An ELISA kit (R&D Systems, Minneapolis, MN, USA) was used to determine the amount of VEGF protein in the CM as reported previously (Biroccio et al., 2000) .
Bcl-2 and bcl-xL protein expression levels were determined as described (Biroccio et al., 2000; Del Bufalo et al., 2002a) . To control for protein loading, b-actin was used and detected by an anti-human b-actin (clone I-19, SC-1616, Santa Cruz Biotechnology, Santa Cruz, CA, USA).
In vitro and in vivo angiogenesis assay
Cell proliferation was measured by the colorimetric assay as described previously (Iervolino et al., 2002) . Exponentially growing HUVEC and HMVEC endothelial cells were seeded in 96-well plates (5 Â 10 3 cells/well) and incubated for 24 h in complete medium in sextuplicates. Thereafter, cells were starved for 24 h in SFM, then incubated in the presence of serum (positive control), the SFM (negative control), or the CM obtained from the two bcl-2 transfectants untreated or treated with antisense oligonucleotide 4625 or 4626 prior to exposure to hypoxia for 24 h. Cell proliferation was measured after 48 h.
The ability of CM from oligonucleotide-treated bcl-2 transfectants to modulate in vivo neovascularization was investigated by use of a matrigel assay as described previously (Biroccio et al., 2000) . Matrigel basement membrane matrix was purchased from BD Biosciences (Bedford, MA, USA).
Statistical analysis
A two-sample t-test was performed to compare VEGF protein secretion in cells exposed to various conditions. The Wilcoxon's rank test was used to compare endothelial cell proliferation under different conditions and the haemoglobin content in the various matrigel pellets.
Abbreviations FCS, fetal calf serum; SFM, serum-free medium; CM, conditioned medium; HUVEC, human umbilical endothelial cells; HMVEC, human microvascular endothelial cells; TUNEL, TdT-mediated dUTP-biotin nick-end labeling assay; VEGF, vascular endothelial growth factor.
